Background The T-box transcription factor Brachyury was recently reported to be upregulated and associated with prognosis in solid tumors. Here, we proposed to evaluate the potential use of Brachyury protein expression as a new prognostic biomarker in gastrointestinal stromal tumors (GIST). Methods Brachyury protein expression was analyzed by immunohistochemistry in a cohort of 63 bona fide GIST patients. Brachyury expression profiles were correlated with patients' clinicopathological features and prognostic impact. Additionally, an in silico analysis was performed using the Oncomine database to assess Brachyury alterations at DNA and mRNA levels in GISTs. Results We found that Brachyury was overexpressed in the majority (81.0 %) of primary GISTs. We observed Brachyury staining in the nucleus alone in 4.8 % of cases, 23.8 % depicted only cytoplasm staining, and 52.4 % of cases exhibited both nucleus and cytoplasm immunostaining. The presence of Brachyury was associated with aggressive GIST clinicopathological features. Particularly, Brachyury nuclear (with or without cytoplasm) staining was associated with the presence of metastasis, while cytoplasm sublocalization alone was correlated with poor patient survival.
Introduction
Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal tumors of the gastrointestinal tract, representing 10-20 cases per million in the world [1] [2] [3] . GISTs present driver oncogenic mutations of receptor tyrosine kinases KIT and PDGFRA and, less frequently, of the BRAF signal transduction molecule [4] [5] [6] . The discovery that KIT-mutant GISTs respond positively to the tyrosine kinase inhibitor imatinib mesylate has significantly improved the prognosis of this disease [7] [8] [9] . In fact, about 85 % of patients with metastatic GIST exhibited substantial clinical benefit from imatinib treatment [10] . The median survival of patients treated with the current therapy is about 5 years, and 34 % of them survive more than 9 years [3] . However, despite all of these improvements, disease progression occurs in approximately 75 % of the patients [10, 11] . Several prognostic parameters are used in GIST management, such as tumor size, location, mitotic index and KIT/PDGFRA mutations, yet many GISTs still behave unpredictably. Thus, it is crucial to find new biomarkers for GIST prognosis.
The T-box transcription factor Brachyury plays a key role during early embryo gastrulation, a typical process of epithelial-mesenchymal transition (EMT) [12, 13] . Brachyury involvement in cancer was initially limited to chordomas, being currently its main etiological factor [14] . More recently, it has been associated with tumor aggressiveness in several types of cancer cells, ultimately promoting invasion and metastasis [15] [16] [17] [18] [19] [20] [21] [22] . Our group has recently described Brachyury as a new and important marker of poor prognosis, cell invasion and metastasis in prostate cancer patients, where it was also associated with higher EMT and stemness expression profiles [19] . Taking into account the important role of Brachyury in tumorigenesis and the need for new biomarkers in GIST, we aimed to examine whether Brachyury immunostaining is associated with GIST prognosis and aggressiveness. Herein, we report that Brachyury is associated with GIST metastasis and patient outcome. Importantly, we suggest Brachyury as a new biomarker for GIST prognosis.
Materials and methods

Tissue samples
Paraffin-embedded tumor samples from 63 primary GISTs were obtained from the Pathology Department of Barretos Cancer Hospital, São Paulo, Brazil, and Garcia de Horta Hospital, Almada, Portugal. Samples were previously classified according to Fletcher and collaborators' criteria and risk group [23] and characterized immunohistochemically for CD117, S100, Ki67 and DOG1 as well as molecularly for KIT (exons 9, 11, 13, 17), PDGFRA (exons 12, 14, 18), BRAF (V600E) and TERT promoter mutations [24] [25] [26] . The cohort comprised 93.7 % of CD117-positive cases, 71.1 % of KIT, 18.3 % of PDGFRA and 1.6 % of TERT-mutated GISTs. Thirty-six (57.1 %) patients were male and 27 (42.9 %) female with a median age of 61 years (range 10-89). Clinicopathological characteristics available for GIST patients are the following: 4 (7.6 %) of 53 patients had very low Fletcher risk, 10/53 (18.9 %) low risk, 12/53 (22.6 %) intermediate risk and 27/53 (50.9 %) high risk; 24 (42.8 %) of 56 patients present metastasis at diagnosis. The diagnosis of metastasis was based on unequivocal imaging findings; 38 (80.9 %) of 47 patients received R0, 10.6 % (5/47) received R1 and 8.5 % (2/47) received R2 surgery. Twenty-seven (48.2 %) of 56 patients were treated with imatinib (25 patients with 400 mg/daily and 2 with 800 mg/daily). At the end of follow-up, 24.6 % (15/61) died because of the disease and 4.9 % (3/61) because of unrelated causes; 42.6 % of patients (26/61) were alive without disease and 27.9 % (17/61) had disease. The project was previously approved by the local ethics committee (no. 554/2011).
Immunohistochemistry analysis
For immunohistochemistry analyses, tissue microarray (TMA) blocks were performed, containing three representative areas of each GIST tissue (1 mm diameter core). Representative 4-lm-thick sections were subjected to immunohistochemical analysis using the streptavidin-biotin peroxidase complex system (UltraVision Large Volume Detection System Anti-Polyvalent, HRP; LabVision Corp.), as previously described [19] (Supplementary Fig S1) , using the primary antibody raised against Brachyury (sc-20109: Santa Cruz Biotechnology, Inc.) [16, 19, [27] [28] [29] . Tumor samples were evaluated for extension (percentage of cytoplasm-positive cells: 0, negative; 1, \25 % positive cells; 2, 26-50 % positive cells; 3, [50 % positive cells) and intensity (0, negative; 1, weak; 2, moderate; 3, strong) of the immunoreactions. The score used for cytoplasm staining was the sum of the extension and the staining intensity. Samples with scores 0-2 were considered negative, and those with scores 3-6 were considered positive. Brachyury nuclear staining was also evaluated and considered negative (\25 % of the cells with positive nuclei staning) or positive (C25 % of the cells depicting nuclear staining). The final score of Brachyury staining was the combination of both cytoplasm and nuclear staining, negative (negative for both subcellular locations) and positive (positive for cytoplasm and/or nuclear staining).
In silico microarray data analyses
Brachyury expression was assessed in two data sets containing specific information for mRNA expression (Cho [30] and Bittner, non published data [31] ) and in two data sets with information for DNA copy number variation (Barretina [32] and Berouklim [33] ) in GIST samples extracted from the Oncomine database [31] . Brachyury expression is defined as Log2 median-centered intensity values for each probe (206524_at, ILMN-1794551 and AI337100) and DNA copy number variation as Log2 copy number units (probe 06-166496598). Microarray coexpression studies in five GIST samples were extracted from Subramanian data set [34] . Microarray expression profiles were clustered by functional importance and signaling pathways using DAVID v6.7 bioinformatic tool (The Database for Annotation, Visualization and Integrated Discovery) [35, 36] , as previously described [19] .
Statistical analyses
Correlations between Brachyury expression and available clinicopathological data were performed using Pearson's chisquare test (v 2 -test). Cumulative survival probabilities were calculated using the Kaplan-Meier method. Differences between survival rates were tested using the log-rank test. Statistical analysis was performed using SPSS software for Windows, version 19.0. Simple comparisons between expression levels from the Oncomine database were analyzed by Student's t test using Prism GraphPad software (version 5.0a). The levels of significance in the statistical analysis are indicated as * p \ 0.05, ** p \ 0.01 or *** p\0.001.
Results
Brachyury is overexpressed in GISTs
An immunohistochemistry analysis of Brachyury expression in a cohort of 63 GISTs was performed. Representative images of Brachyury staining are shown in Fig. 1 . We found that Brachyury is absent or expressed at very low levels in normal tissues (epithelial gastric cells) adjacent to tumor (Fig. 1a-i ) and that 19.0 % (12/63) of GISTs are negative for Brachyury (both nucleus and cytoplasm) (Fig. 1a, b -ii). In GIST-positive tissues (81.0 %; n = 51/63), Brachyury was found at the cytoplasm and/or nuclear level (Fig. 1a- iii, b-iv). Specifically, we found Brachyury staining only in the nucleus for 3/63 (4.8 %) cases, 15/63 (23.8 %) only in the cytoplasm and 33/63 (52.4 %) in both the nucleus and cytoplasm (Fig. 1b) . For statistical analysis, GIST tumors were classified into two groups: negative (negative for both cytoplasm and nuclear staining) vs. positive (positive for both cytoplasm and/or nuclear staining) or in three groups based on Brachyury subcellular localization: negative (12/63; 19.1 %) vs. cytosolic staining alone (15/63; 23.8 %) vs. nuclear staining (with or without cytoplasm staining: 36/63; 52.4 %) ( Tables 1, 2 ).
Brachyury nuclear sublocalization is associated with the presence of metastasis
We further assessed the correlation of Brachyury staining with GIST clinicopathological and molecular features ( Table 1, 2) . Using univariate analysis we found a statistically significant association between Brachyury staining and subcellular localization and PDGFRA mutation status (p = 0.005 and p = 0.003, respectively; Table 1 ). No significant association between Brachyury levels and other variables analyzed (KIT and TERT mutation status, and CD117, DOG1 and S100) was found (Table 1) . Concerning the clinicopathological impact, we found that Brachyury in the nucleus was strongly associated with presence of metastasis (p = 0.020; Table 2 ). No associations were found with the type of resection (R0 vs. R1 vs. R2) and with treatment (imatinib vs. no treatment) (data not shown).
Brachyury association with GIST aggressiveness evidenced by in silico microarray analysis
In silico analyses of Brachyury mRNA expression in GISTs were performed to extend and validate our findings at the protein level. Data were extracted from two microarray expression data sets available in Oncomine with more than two cases analyzed [31] . Brachyury was statistically upregulated in both data sets (Fig. 2a) . In an attempt to understand if increased expression of Brachyury in GISTs could be due to gene amplification, we analyzed copy number alterations in two additional data sets (Barretina [32] and Beroukhim [33] ). No Brachyury gene amplification was found in GIST cell lines, primary GISTs or GIST subtypes (Fig. 2b ).
An analysis of genes coexpressed with Brachyury in Oncomine microarray data [31] was performed to identify putative partners and pathways associated with Brachyury in GISTs (Fig. 3) . As shown in Fig. 3 , genes coexpressed with Brachyury were functionally clustered in oncogenic pathways (MAPK, Wnt, PPAR, ErbB and TGF-beta signaling pathway). Moreover, a strong association with pathways involved in the cell metabolism/microenvironment was also identified (PPAR, insulin/IGF-1, adipocytokine signaling pathways, arginine, proline, alanine, aspartate and glutamate metabolism, panthothenate and CoA biosynthesis, biosynthesis of unsaturated fatty acids). This analysis suggests that Brachyury could promote GIST aggressiveness by regulating multiple oncogenic pathways.
Overexpression of Brachyury in the cytoplasm are predictive of poor prognosis
Regarding disease-specific survival (univariate analysis) and clinicopathological features, we found that lower survival was significantly associated with mixed subtype (p = 0.047) and Fletcher's risk malignancy (p = 0.045) (data not shown). Overall Brachyury overexpression exhibited a tendency to be associated with poor patient prognosis (p = 0.079; Table 3 ; Fig. 4a ). We then analyzed the prognostic impact of Brachyury subcellular localization in order to better understand the importance of Brachyury compartmentalization. We observed that all Brachyury-negative GIST patients were alive (follow-up = 44.9 ± 37.5 months), and there was a tendency for Brachyury cytoplasm staining to be associated with the status of GIST patients [alive without disease: 11.5 % \alive with disease: 23.5 % \dead due to disease: 40.0 %] (Table 3) . Importantly, Brachyury positivity in the cytoplasm alone was associated with reduced disease-specific survival, nuclear (with or without cytoplasm)-positive cases present an intermediate survival, and the GIST negative cases have the best patient outcome (p = 0.036; Fig. 4b ; Table 3 ). The low number of cases precluded multivariate analysis of the studied parameters.
Discussion
The treatment of GISTs was revolutionized by the introduction of imatinib, a potent KIT inhibitor, as the first option for KIT/PDGFRA-driven mutation and metastatic disease [37, 38] . However, a subset of patients develops imatinib-resistant GISTs and eventually progresses to more aggressive disease. Therefore, new prognostic biomarkers are needed. We previously showed that molecular alterations in RKIP [39] and MCT1 and its chaperone (CD147) [24] are associated with GIST poor overall survival, but do not aid in predicting tumor resistance or metastatic disease, which can preclude patient treatment. T-box transcription factor Brachyury was recently described to be overexpressed in several tumor types [17-20, 40, 41] , playing an important role in EMT processes, metastasis and stem cell-like features [15] [16] [17] [18] [19] [41] [42] [43] . Due Fig. 3 Microarray expression analysis of genes coexpressed with Brachyury. a Microarray expression profiles of Brachyury coexpressed genes were clustered by functional role and signaling pathways using DAVID bioinformatics tool. Brachyury coexpressed genes were organized by their functional definition. Clusters with statistical significance and higher enrichment scores were associated with tumor aggressiveness, microenvironment modulation and embryonic tissue development. b KEGG signaling pathway subanalysis. Pathways involved in tumor aggressiveness (MAPK, WNT, Erb, PPAR, TGF-beta signaling pathways) and tumor metabolism and invasion were the ones with a higher number of genes coexpressed with Brachyury. *p \ 0.05. NS non significant to its role in the EMT process and involvement in metastatic development in solid tumors [17, 19] , Brachyury is positioned as a promising therapeutic target for advanced cancer patients [40, 44] . To our knowledge, this is the first study that investigates Brachyury immunostaining and its relevance as a novel marker of aggressiveness in GIST. In agreement with our previous study in prostate cancer [19] , we found that Brachyury is overexpressed in GISTs, which may reflect a role in GIST biology. We previously described that Brachyury can be expressed in both the cytoplasm and nucleus of prostate carcinomas [19] . We also showed that cytoplasm Brachyury expression is remarkably related to more aggressive prostate carcinomas (higher Gleason scores), and nuclear expression is associated with invasive carcinomas, being preferentially expressed in prostate metastasis [19] . In the present study, we also show the importance of subcellular Brachyury location. In primary GISTs, nuclear sublocalization (with or without cytoplasm) relates with the presence of metastasis at diagnosis, in accordance with its role as a master regulator of EMT, being a therefore new putative biomarker of GIST aggressiveness. Further studies in a larger series, and in particular the comparison between primary and metastatic tissue of GISTs, are necessary to validate these findings.
It has been described that resected metastasis, primary and secondary GISTs that progress upon imatinib treatment reveal secondary KIT mutations as a common mechanism of resistance. However, a subset of GIST patients lacks KIT expression, indicating that KIT oncogenic programs have been supplanted by alternative oncogenic drivers yet to be unidentified [45, 46] . Our data suggest that Brachyury expression and its effect on tumor progression are not related to KIT or PDGFRA mutations. In silico microarray coexpression analysis indicates that Brachyury could promote GIST aggressiveness and therapy resistance by modulating several biological processes, such as oncogenic pathways, tumor microenvironment and immune response. In fact, immune and metabolic pathways are gaining relevance in GIST [28] , namely influencing patient response to imatinib therapy [47] [48] [49] . Further investigations on larger cohorts and functional studies will be required to validate these data. The impact of Brachyury in poor prognosis has already been described for early stages of colorectal cancer [20] , lung cancer [21] , oral squamous cell carcinomas [17] and prostate cancer [19] . In our series of GISTs, we stratify GIST patients into three distinct groups with differential survival probabilities based on Brachyury subcellular localization. We found a significant correlation between Brachyury in the cytoplasm alone and worse prognosis, a group with intermediate prognosis corresponding to the presence of Brachyury in the nucleus (with or without cytoplasm) and a subset of patients with good prognosis lacking Brachyury expression.
A growing number of transcription-dependent and -independent functions have been described [50] . Although the role of Brachyury protein in the cytoplasm has yet to be determined, we hypothesize that: (1) it can interact with different partners in order to regulate oncogenic signaling pathways, probably because of post-translation regulation, as described for other transcription factors [50, 51] ; (2) it could be a consequence of a dynamic process of protein shuttling between cytosol-nucleus; or (3) it could be a consequence of an enhanced translation process resulting in accumulation in the cytosol. These results, together with a recent study showing that Brachyury mediates tumor resistance to conventional cytotoxic therapies [22] and with the possibility that Brachyury-expressing tumor cells can be lysed via immunotherapy by Brachyury-based vaccines [40, 44, 52] , highlight Brachyury as a promising therapeutic target for cancer treatment, probably in combination with other drugs, such as imatinib.
Conclusion
In the present study, we assessed Brachyury immunostaining in GIST for the first time. Our results highlight the relevance of Brachyury in GIST aggressiveness, pointing to a potential novel prognostic biomarker and therapeutic target.
